News Roche Holding AG

Stocks

ROP

CH1499059983

Pharmaceuticals

End-of-day quote Swiss Exchange Other stock markets 2026-06-05			5-day change	1st Jan Change
327.10 ^CHF	+0.77%		0.00%	-0.34%

Jun. 12	Roche Receives FDA Approval for the First Companion Diagnostic to Assess PTEN Protein in People Living with Prostate Cancer	CI
Jun. 12	Jazz Pharmaceuticals lung cancer drug fails main trial goal	RE

All News

Mentions Relevance

Jun. 12	Roche Receives FDA Approval for the First Companion Diagnostic to Assess PTEN Protein in People Living with Prostate Cancer	CI
Jun. 11	Roche Announces FDA Grants Priority Review For Roche's Tecentriq For A Certain Type Of Stage III Colon Cancer	CI
Jun. 11	Roche's Tecentriq, Chemotherapy Combo Gets US FDA Priority Review for Colon Cancer	MT
Jun. 11	FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer	BU
Jun. 11	Roche Announces IVDR Approval For VENTANA MMR RxDx Panel Companion Diagnostic Across Multiple Cancer Types And Therapies	CI
Jun. 10	Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon	RE
Jun. 09	Roche sticks to German investment after Eli Lilly cuts	RE
Jun. 08	Roche Holding AG - Shareholder/Analyst Call
Jun. 08	Roche Licenses Nurix Therapeutics Blood-Cancer Drug for Up to $2.3 Billion -- Update	DJ
Jun. 08	Roche Holding AG And Nurix Therapeutics, Inc. Announce Global Collaboration To Co-Develop And Co-Commercialise Potential Best-In-Class BTK Degrader Bexobrutideg Across Malignant Haematology, Immunology And Neurology	CI
Jun. 08	Roche enters cancer drug deal worth up to $2.3 billion with Nurix Therapeutics	RE
Jun. 08	ROCHE HOLDINGS AG : Jefferies keeps a Sell rating	ZD
Jun. 08	Roche enters $2 billion cancer drug agreement with Nurix Therapeutics	RE
Jun. 08	Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics	DJ
Jun. 08	Roche, Nurix Therapeutics to Develop, Commercialize BTK Degrader Bexobrutideg	MT
Jun. 05	Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial	RE
Jun. 05	Zealand touts promising tolerability data for obesity drug in mid-stage study	RE
Jun. 05	Swiss stocks - Factors to watch on June 5	RE
Jun. 04	Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection	PR
Jun. 04	Roche chairman flags concern over U.S., China protectionism	RE
Jun. 04	Roche chairman likens US tariff policy to 'blackmail'	RE
Jun. 04	ROCHE HOLDINGS AG : Receives a Sell rating from Jefferies	ZD
Jun. 02	Foundation Medicine Receives Fda Approval for Foundationone Cdx as Companion Diagnostic for Itovebi in Combination with Palbociclib and Fulvestrant	CI
Jun. 02	Roche Receives FDA Acceptance For New Drug Application For Giredestrant In ER-Positive Early-Stage Breast Cancer	CI
Jun. 02	Roche Wins US FDA's Priority Review for Breast Cancer Treatment Giredestrant	MT